LYDIA ROBERT: Open Payments
NPI 1922865336 · FORT WORTH, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$777 in 39 payments from 12 companies in 2025. Trend: 2023 $0 · 2024 $591 · 2025 $777
Food & beverage: $777
| Company | Payments | Amount |
|---|---|---|
| Calliditas Therapeutics US Inc. | 11 | $175 |
| Travere Therapeutics, Inc. | 6 | $154 |
| Novo Nordisk Inc | 5 | $87 |
| Merck Sharp & Dohme LLC | 3 | $65 |
| Amgen Inc. | 3 | $64 |
| AstraZeneca Pharmaceuticals LP | 3 | $60 |
| Otsuka America Pharmaceutical, Inc. | 2 | $48 |
| AKEBIA THERAPEUTICS INC | 2 | $45 |
| ANI Pharmaceuticals, Inc. | 1 | $25 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $22 |
Products named: TARPEYO, Ozempic, PREVYMIS, KRYSTEXXA, FARXIGA, Auryxia, PURIFIED CORTROPHIN GEL, JYNARQUE.
Industry payments across TX — which companies pay providers there.
